Analyzing MMP2 and MMP9 in Patients with Newly Diagnosed Glioblastoma
Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.
This study is testing how levels of certain proteins in the blood relate to brain scans and tumor samples in people who have just been diagnosed with glioblastoma, to see how these levels change during treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Drugs / interventions | chemotherapy, bevacizumab |
| Locations | 1 site (Marseille) |
| Trial ID | NCT03526822 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with newly diagnosed glioblastoma, the most aggressive primary brain tumor in adults. It aims to correlate plasma levels of matrix metalloproteinases MMP2 and MMP9 with their tissue expression and neuro-imaging features. The study will also analyze changes in these plasma levels during the peri-operative period and after radio-chemotherapy. Blood and tumor samples will be collected for detailed analysis using enzyme-linked immunosorbent assays.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over with imaging suggestive of glioblastoma who are eligible for surgical excision and subsequent radiotherapy chemotherapy.
Not a fit: Patients with nonoperable lesions or those who have previously undergone treatment for glioblastoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of glioblastoma biology and improve treatment strategies for patients.
How similar studies have performed: While studies have explored MMPs in glioblastoma, this specific correlation with neuro-imaging features is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete) * Candidate for concomitant and adjuvant radiotherapy chemotherapy (Stupp protocol) * Patient having signed an informed consent * Patient having undergone a preoperative MRI Exclusion Criteria: * Existence of a contraindication to the MRI * Nonoperable lesion * History of radiotherapy and / or chemotherapy for this lesion * Scalability of a low grade lesion * Person in emergency situation, a legal person of legal age (guardianship, guardianship or legal guardianship), or unable to express his or her consent * No affiliation to a social security scheme (beneficiary or beneficiary) * Pregnant or lactating woman
Where this trial is running
Marseille
- Assistance Publique Hôpitaux de Marseille — Marseille, France (Recruiting)
Study contacts
- Study coordinator: Emeline TABOURET, PH
- Email: emeline.tabouret@ap-hm.fr
- Phone: 491385500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.